A monoclonal antibody used to treat asthma and eczema can improve survival for patients with moderate to severe COVID-19, a clinical trial conducted at UVA Health suggests. The small trial, designed and led by Jennifer Sasson, MD, found that dupilumab improved patient survival at 60 days and reduced the number of patients who needed intensive […]